Preview complete
The prescreener preview is complete. You may now close the preview.
Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY
Are you a patient with moderate to severe plaque psoriasis?
Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Detailed Description
This is a phase 1 study to evaluate the feasibility, safety, clinical and immune effects of DC/MM fusion vaccine in combination with Elranatamab in participants with relapsed/refractory multiple myeloma. The DC/MM fusion vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells. This vaccine is individualized for each participant using dendritic cells (type of immune cells) from each participant. GM-CSF contains a substance that helps make more white blood cells. This medication is being used to possibly increase the effectiveness of the DC/MM fusion vaccine.
The U.S. Food and Drug Administration (FDA) has not approved DC/MM fusion vaccine as a treatment for Relapsed or Refractory Multiple Myeloma.
The FDA has not approved GM-CSF as a treatment for Relapsed or Refractory Multiple Myeloma.
The FDA has approved elranatamab as a treatment option for Relapsed or Refractory Multiple Myeloma.
The research study procedures include screening for eligibility, in-clinic visits, blood tests, urine tests, study drug subcutaneous (under the skin) injections, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission (PET) scans, and bone marrow biopsies and aspirations (or collections).
Participants will receive study treatment for up to 12 cycles (28-day cycles) and will be followed for up to 5 years.
It is expected that about 25 people will take part in this research study.
Pfizer is funding this research study by providing one of the study drugs, Elranatamab.
Simple Text Block
You can use content blocks to arrange your articles, large texts,
instructions. Combine these blocks with media blocks to add
illustrations and video tutorials. You can use various content blocks to
work with your text. Add quotations, lists, buttons. Select your text to
change its formatting or add links. You can use various content blocks
to work with your text. Add quotations, lists, buttons. Select your text
to change its formatting or add links.
Call 1800-9860-568 now to find out if you are eligible.
Check your eligibility
Take up this questionnaire to help us determine if you have symptoms that are common to this clinical study. If you have the common symptoms, you may be eligible to take part in the study.
Age
None - None
Gender
All
NCT ID
NCT06799026
Phase
1
Status
Recruiting Now
Medical Condition
Multiple Myeloma
How is Plaque Psoriasis treated?
Medical Condition
A short sentence to introduce what to expect in the about condition
section
Learn moreThe Study
A short sentence to introduce what to expect in the about condition
section
Learn moreAbout Clinical Trials
A short sentence to introduce what to expect in the about condition
section
Learn moreYour Journey
01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and
then once a week for 12 weeks. Etanercept, as well as study related
medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local
study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after
completing the study. No visits are required after participation is
complete.